Asset Details
Do you wish to reserve the book?
Adjuvant treatment with Wu-Zi-Yan-Zong formula for abnormal sperm parameters associated with male infertility: a meta-analysis of randomized controlled trials
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Adjuvant treatment with Wu-Zi-Yan-Zong formula for abnormal sperm parameters associated with male infertility: a meta-analysis of randomized controlled trials
Do you wish to request the book?
Adjuvant treatment with Wu-Zi-Yan-Zong formula for abnormal sperm parameters associated with male infertility: a meta-analysis of randomized controlled trials
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Adjuvant treatment with Wu-Zi-Yan-Zong formula for abnormal sperm parameters associated with male infertility: a meta-analysis of randomized controlled trials
2025
Overview
Wu-Zi-Yan-Zong (WZYZ) formula is a traditional Chinese botanical drug that has been used to treat male infertility. This meta-analysis aims to evaluate its effectiveness of the WZYZ formula as an adjuvant therapy for treating abnormal sperm parameters associated with male infertility.
A comprehensive literature search was conducted using PubMed, Embase, Cochrane Library, Web of Science, SinoMed, Wanfang, and CNKI databases until December 12, 2024 to identify randomized controlled trials (RCTs) that assessed the effectiveness of the WZYZ formula as an adjuvant therapy for treating abnormal sperm parameters associated in men with infertility. For dichotomous data, the pooled results were summarized as risk ratio (RR) with 95% confidence intervals (CI), while continuous data were expressed as pooled weighted mean difference (WMD) with 95% CI.
A total of 11 RCTs involving 951 men were identified. The pooled results showed that the WZYZ formula, when combined with control treatment, significantly improved the pregnancy rate of female partners (RR 1.68; 95% CI 1.34-2.11), semen volume (WMD 0.58 mL; 95% CI 0.28-0.89), sperm concentration (WMD 6.87 × 10
/mL; 95%CI 4.24-9.51), total sperm motility (WMD 15.55%; 95% CI 10.38-20.72), forward grade (a) sperm motility (WMD 5.44%; 95% CI 1.86-9.01), forward grade (a + b) sperm motility (WMD 7.14%; 95% CI 4.04-10.23), abnormal sperm morphology (WMD -10.38%; 95% CI -15.72 to -5.03), and activity of the acrosome enzyme (WMD 8.02 × 10
μIU; 95% CI 3.58-12.46.
Adjuvant treatment with WZYZ formula significantly improves the pregnancy rate of female partners by improving several semen parameters in infertile men with abnormal sperm parameters. However, further well-designed RCTs with larger sample sizes are necessary to definitively determine the efficacy and safety of the WZYZ formula in treating abnormal sperm parameters associated with male infertility.
https://www.crd.york.ac.uk/PROSPERO/view/CRD42024629510.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
